Background: ABX464 (obefazimod) is a small molecule that upregulates a single microRNA (miR-124) in immune cells and reduces the production of various inflammatory cytokines and chemokines. Objective: We assessed the efficacy and safety of the standard of care (SoC) plus oral obefazimod (SoC plus ABX464). 50 mg once daily. versus the SoC plus placebo for prevention of severe acute res... https://cosmeticssquadets.shop/product-category/toys-activity-books/